Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial.

S. Faderl,Meir Wetzler,David A. Rizzieri,Gary J. Schiller,Madan Jagasia,Robert K. Stuart,Siddhartha Ganguly,David Avigan,Michael Craig,Robert H. Collins,Michael B. Maris,Tibor Kovacsovics,Stuart L. Goldberg,Karen Seiter,Parameswaran Hari,Farhad Ravandi,Eunice S. Wang,Stephen Eckert,Dirk Huebner,Hagop M. Kantarjian

Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial.

2011

6503^ Background: This is the first phase III, prospective, randomized, blinded trial to evaluate the efficacy and safety of clofarabine (CLO) in combination with ara-C compared to ara-C alone in o...

Keywords:

Clofarabine
Physical therapy
Acute myelogenous leukemia (AML)
Cytarabine
Cancer research
Medicine
Pathology
Oncology
Internal medicine
Refractory
older patients

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations